tanezumab + diclofenac

Tanezumab + diclofenac is a **combination therapy** of two drugs, tanezumab and diclofenac, investigated for the treatment of moderate-to-severe **osteoarthritis pain**, particularly of the knee or hip. **Tanezumab** is a monoclonal antibody that inhibits **nerve growth factor (NGF)**, reducing pain signaling. **Diclofenac** is a small molecule **nonsteroidal anti-inflammatory drug (NSAID)** that reduces inflammation by inhibiting **cyclooxygenase enzymes (COX-1 and COX-2)**. Tanezumab is administered subcutaneously, and diclofenac is taken orally. Early studies found that this combination produced greater short-term improvements in pain and function versus diclofenac alone, but **risks of adverse joint events** (including rapidly progressive osteoarthritis and possible osteonecrosis) led to concerns about the safety of this combination, and researchers concluded the potential harms may outweigh the benefits[1][3].